Artiva Biotherapeutics’ stock price has plummeted, raising concerns about the company’s financial health, despite its promising scientific endeavors in developing NK cell-based therapies for autoimmune diseases and cancers.

Artiva Biotherapeutics, a clinical-stage biotech company, is pioneering NK cell-based therapies for autoimmune diseases and cancer treatment, with its lead product candidate AlloNK showing promise in ongoing trials.